EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)

Brett King, Maryanne M Senna, Natasha A Mesinkovska, Charles Lynde, Matthew Zirwas, Catherine Maari, Vimal H Prajapati, Sheetal Sapra, Pawel Brzewski, Lawrence Osman, Sameh Hanna, Marni C Wiseman und 2 weitere

Journal of the American Academy of Dermatology · 2024-11 · 91 (5) · 880-888

DOI: 10.1016/j.jaad.2024.06.097 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of the American Academy of Dermatology, 2024-11. Verfasst von Brett King und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Yale School of Medicine, New Haven, Connecticut. Electronic address: brett.king@yale.edu. Hauptthemen laut MEDLINE: Alopecia Areata, Janus Kinase Inhibitors, Pyrazoles, Pyrimidines. Die Arbeit wurde bisher 117-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Concert Pharmaceuticals, Sun Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Alopecia areata (AA) is a hair loss disorder that can seriously impact quality of life. Janus kinase (JAK) inhibitors, including deuruxolitinib, have previously demonstrated significant hair regrowth in AA. OBJECTIVE: The Phase 3 THRIVE-AA1 randomized, double-blinded, placebo-controlled trial (NCT04518995) evaluated the safety and efficacy of the oral JAK1/JAK2 inhibitor deuruxolitinib in adult patients with AA. METHODS: Patients aged 18-65 years with ≥50% hair loss were randomized to deuruxolitinib 8 mg twice daily, deuruxolitinib 12 mg twice daily, or placebo for 24 weeks. The primary end point was the percentage of patients achieving a Severity of Alopecia Tool score ≤20. A key secondary end point was the percentage of satisfaction of hair patient-reported outcome responders. RESULTS: Significantly higher proportions of patients taking deuruxolitinib met the primary end point (8 mg 29.6%; 12 mg 41.5% versus placebo 0.8%). Both deuruxolitinib doses achieved significant improvements in all secondary end points versus placebo, including satisfaction of hair patient-reported outcome (8 mg 42.1%; 12 mg 53.0% versus placebo 4.7%). Most treatment-emergent adverse events were mild or moderate, consistent with other oral JAK inhibitors. LIMITATIONS: Further studies are required to understand longer-term safety, efficacy, and impact of treatment cessation. CONCLUSION: Both doses of deuruxolitinib were effective for hair regrowth. Patient satisfaction aligned with hair growth.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alopecia AreataJanus Kinase InhibitorsPyrazolesPyrimidinesPyrrolesAdolescentAdultAgedFemaleHumansMaleMiddle AgedYoung AdultAdministration, OralDose-Response Relationship, DrugDouble-Blind MethodJanus Kinase 1Patient Reported Outcome MeasuresPatient SatisfactionSeverity of Illness IndexTreatment Outcome

Stichwörter der Autor:innen

Janus kinase (JAK) inhibitorPhase 3Severity of Alopecia Tool (SALT)THRIVE-AA1alopecia areatadeuruxolitinib

Substanzen

Janus Kinase 1Janus Kinase InhibitorsPyrazolesPyrimidinesPyrrolesDeuruxolitinib

Autor:innen und Institutionen

  • Department of Dermatology, Yale School of Medicine, New Haven, Connecticut. Electronic address: brett.king@yale.edu.
  • Department of Dermatology, Lahey Hair Loss Center of Excellence, Lahey Hospital and Medical Center, Burlington, Massachusetts.
  • Department of Dermatology, University of California, Irvine, California.
  • Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Lynderm Research Inc., Probity Medical Research, Markham, Ontario, Canada.
  • DOCS Dermatology, Columbus, Ohio.
  • Faculty of Medicine, Department of Medicine, University of Montreal, Montreal, Quebec, Canada.

Förderung

  • Concert Pharmaceuticals
  • Sun Pharma

Zitieren

APA

King, B., Senna, M. M., Mesinkovska, N. A., Lynde, C., Zirwas, M., Maari, C., Prajapati, V. H., Sapra, S., Brzewski, P., Osman, L., Hanna, S., Wiseman, M. C., Hamilton, C., & Cassella, J. (2024). Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1). Journal of the American Academy of Dermatology, 91(5), 880-888. https://doi.org/10.1016/j.jaad.2024.06.097

Vancouver

King B, Senna MM, Mesinkovska NA, Lynde C, Zirwas M, Maari C, et al. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1). Journal of the American Academy of Dermatology. 2024;91(5):880-888. doi:10.1016/j.jaad.2024.06.097

BibTeX
@article{King2024,
  author = {King, Brett and Senna, Maryanne M and Mesinkovska, Natasha A and Lynde, Charles and Zirwas, Matthew and Maari, Catherine and Prajapati, Vimal H and Sapra, Sheetal and Brzewski, Pawel and Osman, Lawrence and Hanna, Sameh and Wiseman, Marni C and Hamilton, Colleen and Cassella, James},
  title = {Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)},
  journal = {Journal of the American Academy of Dermatology},
  year = {2024},
  volume = {91},
  number = {5},
  pages = {880--888},
  doi = {10.1016/j.jaad.2024.06.097}
}
Kostenlos starten →